nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Aprepitant—CYP3A4—breast cancer	0.00296	1	CrCbGaD
Fosaprepitant—TACR1—GPCR ligand binding—WNT1—breast cancer	0.000825	0.00369	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IFNG—breast cancer	0.00082	0.00366	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—breast cancer	0.000786	0.00351	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTGER1—breast cancer	0.000784	0.00351	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL3—breast cancer	0.00077	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PDE2A—breast cancer	0.00077	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCL27—breast cancer	0.00077	0.00344	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	0.000762	0.00341	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—breast cancer	0.000762	0.00341	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR2—breast cancer	0.000755	0.00337	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL2—breast cancer	0.000755	0.00337	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PTHLH—breast cancer	0.000746	0.00334	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDKN1B—breast cancer	0.000744	0.00333	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—breast cancer	0.000731	0.00327	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—breast cancer	0.00073	0.00326	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL2—breast cancer	0.000728	0.00326	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDNRB—breast cancer	0.000723	0.00323	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—WNT10B—breast cancer	0.000717	0.00321	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCND1—breast cancer	0.00071	0.00317	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PDE2A—breast cancer	0.000699	0.00313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL27—breast cancer	0.000699	0.00313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL3—breast cancer	0.000699	0.00313	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—breast cancer	0.000689	0.00308	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CALCA—breast cancer	0.000657	0.00294	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL12—breast cancer	0.000642	0.00287	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR4—breast cancer	0.000642	0.00287	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—breast cancer	0.00061	0.00273	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK3—breast cancer	0.000586	0.00262	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—breast cancer	0.000585	0.00261	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—breast cancer	0.000584	0.00261	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR1—breast cancer	0.00058	0.00259	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—breast cancer	0.00057	0.00255	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—breast cancer	0.000568	0.00254	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—JUN—breast cancer	0.000567	0.00253	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RGS2—breast cancer	0.000563	0.00252	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CTNNB1—breast cancer	0.000562	0.00251	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—breast cancer	0.000557	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCL20—breast cancer	0.000557	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LGR6—breast cancer	0.000545	0.00244	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCDC88C—breast cancer	0.000545	0.00244	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—LPAR1—breast cancer	0.000539	0.00241	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—breast cancer	0.000531	0.00237	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—breast cancer	0.000521	0.00233	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SFRP1—breast cancer	0.00052	0.00232	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GPER1—breast cancer	0.00052	0.00232	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RGS2—breast cancer	0.000511	0.00229	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PDE4D—breast cancer	0.000509	0.00228	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCL20—breast cancer	0.000505	0.00226	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	0.000503	0.00225	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NMBR—breast cancer	0.000498	0.00223	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CNR2—breast cancer	0.000496	0.00222	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—breast cancer	0.000495	0.00221	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—LPAR1—breast cancer	0.00049	0.00219	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—breast cancer	0.000468	0.00209	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CUL5—breast cancer	0.000463	0.00207	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HEYL—breast cancer	0.000463	0.00207	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTGER1—breast cancer	0.000463	0.00207	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PDE4D—breast cancer	0.000462	0.00207	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CNR2—breast cancer	0.000451	0.00201	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RSPO3—breast cancer	0.000436	0.00195	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—breast cancer	0.000428	0.00191	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR2—breast cancer	0.000427	0.00191	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL2—breast cancer	0.000427	0.00191	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—breast cancer	0.000424	0.0019	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WNT10B—breast cancer	0.000424	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WWOX—breast cancer	0.000424	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—WNT1—breast cancer	0.000424	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PTHLH—breast cancer	0.000422	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL3—breast cancer	0.000413	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDE2A—breast cancer	0.000413	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL27—breast cancer	0.000413	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INHBB—breast cancer	0.000413	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDNRB—breast cancer	0.000409	0.00183	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BMPR2—breast cancer	0.000394	0.00176	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DLL4—breast cancer	0.000394	0.00176	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR2—breast cancer	0.000387	0.00173	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL2—breast cancer	0.000387	0.00173	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTHLH—breast cancer	0.000383	0.00171	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDH5—breast cancer	0.000378	0.00169	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CALCA—breast cancer	0.000371	0.00166	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDNRB—breast cancer	0.000371	0.00166	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SFRP2—breast cancer	0.00037	0.00166	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRLR—breast cancer	0.000364	0.00163	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR4—breast cancer	0.000363	0.00162	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL12—breast cancer	0.000363	0.00162	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	0.000362	0.00162	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLI2—breast cancer	0.000351	0.00157	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VCP—breast cancer	0.000351	0.00157	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	0.000349	0.00156	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEPR—breast cancer	0.000345	0.00154	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	0.000345	0.00154	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—breast cancer	0.000342	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CALCA—breast cancer	0.000337	0.00151	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—breast cancer	0.000335	0.0015	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR4—breast cancer	0.000329	0.00147	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL12—breast cancer	0.000329	0.00147	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR1—breast cancer	0.000328	0.00147	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	0.000326	0.00146	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ARHGDIA—breast cancer	0.000321	0.00144	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FST—breast cancer	0.000313	0.0014	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HEY2—breast cancer	0.000309	0.00138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RPS6KB2—breast cancer	0.000305	0.00137	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RGS2—breast cancer	0.000302	0.00135	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	0.000299	0.00134	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL20—breast cancer	0.000299	0.00133	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR1—breast cancer	0.000298	0.00133	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ITPR1—breast cancer	0.000294	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TLE3—breast cancer	0.000289	0.00129	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LPAR1—breast cancer	0.000289	0.00129	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HEY1—breast cancer	0.000286	0.00128	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DLL1—breast cancer	0.000281	0.00125	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	0.000277	0.00124	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIST1H2BC—breast cancer	0.000276	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIST1H2BK—breast cancer	0.000276	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDE4D—breast cancer	0.000273	0.00122	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRB7—breast cancer	0.000273	0.00122	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CSF2—breast cancer	0.000272	0.00122	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TAB2—breast cancer	0.000268	0.0012	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ITPR1—breast cancer	0.000267	0.00119	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CNR2—breast cancer	0.000266	0.00119	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—breast cancer	0.000266	0.00119	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MMP3—breast cancer	0.000266	0.00119	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	0.000265	0.00118	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DKK1—breast cancer	0.00026	0.00116	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFC—breast cancer	0.000258	0.00115	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JAG2—breast cancer	0.000254	0.00113	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WNT1—breast cancer	0.00025	0.00112	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PLA2G4A—breast cancer	0.00025	0.00112	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CSF2—breast cancer	0.000247	0.0011	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH4—breast cancer	0.000237	0.00106	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GZMB—breast cancer	0.000236	0.00105	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL2—breast cancer	0.000229	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR2—breast cancer	0.000229	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTHLH—breast cancer	0.000226	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BMP2—breast cancer	0.000226	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDNRB—breast cancer	0.000219	0.00098	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PGR—breast cancer	0.000217	0.00097	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—THBS1—breast cancer	0.000216	0.000965	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FLT1—breast cancer	0.000206	0.000921	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF3—breast cancer	0.000205	0.000917	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SQSTM1—breast cancer	0.000205	0.000917	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—breast cancer	0.000204	0.000912	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JAG1—breast cancer	0.000203	0.000905	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH3—breast cancer	0.000202	0.000902	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PARP1—breast cancer	0.000202	0.000902	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CALCA—breast cancer	0.000199	0.000891	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RPS6—breast cancer	0.000197	0.00088	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF4—breast cancer	0.000195	0.000873	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCR4—breast cancer	0.000195	0.00087	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL12—breast cancer	0.000195	0.00087	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PAK1—breast cancer	0.000191	0.000854	CbGpPWpGaD
Fosaprepitant—Hypotension—Docetaxel—breast cancer	0.000188	0.000243	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TCF7L2—breast cancer	0.000188	0.000839	CbGpPWpGaD
Fosaprepitant—Haematuria—Doxorubicin—breast cancer	0.000187	0.000242	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—breast cancer	0.000187	0.000242	CcSEcCtD
Fosaprepitant—Abdominal pain—Paclitaxel—breast cancer	0.000187	0.000242	CcSEcCtD
Fosaprepitant—Body temperature increased—Paclitaxel—breast cancer	0.000187	0.000242	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—breast cancer	0.000187	0.000242	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT2—breast cancer	0.000187	0.000835	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—breast cancer	0.000185	0.000829	CbGpPWpGaD
Fosaprepitant—Angiopathy—Methotrexate—breast cancer	0.000185	0.000239	CcSEcCtD
Fosaprepitant—Vomiting—Mitoxantrone—breast cancer	0.000185	0.000239	CcSEcCtD
Fosaprepitant—Vomiting—Irinotecan—breast cancer	0.000185	0.000239	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—breast cancer	0.000184	0.000238	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—breast cancer	0.000184	0.000238	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—breast cancer	0.000184	0.000237	CcSEcCtD
Fosaprepitant—Rash—Irinotecan—breast cancer	0.000183	0.000237	CcSEcCtD
Fosaprepitant—Rash—Mitoxantrone—breast cancer	0.000183	0.000237	CcSEcCtD
Fosaprepitant—Dermatitis—Mitoxantrone—breast cancer	0.000183	0.000237	CcSEcCtD
Fosaprepitant—Dermatitis—Irinotecan—breast cancer	0.000183	0.000237	CcSEcCtD
Fosaprepitant—Headache—Irinotecan—breast cancer	0.000182	0.000235	CcSEcCtD
Fosaprepitant—Headache—Mitoxantrone—breast cancer	0.000182	0.000235	CcSEcCtD
Fosaprepitant—Hypotension—Capecitabine—breast cancer	0.000182	0.000235	CcSEcCtD
Fosaprepitant—Insomnia—Docetaxel—breast cancer	0.000182	0.000235	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HSP90AA1—breast cancer	0.000181	0.000809	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH2—breast cancer	0.000181	0.000809	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Epirubicin—breast cancer	0.00018	0.000233	CcSEcCtD
Fosaprepitant—Vomiting—Gemcitabine—breast cancer	0.00018	0.000233	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—breast cancer	0.00018	0.000232	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CD—breast cancer	0.000179	0.000802	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Docetaxel—breast cancer	0.000179	0.000231	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—breast cancer	0.000179	0.000231	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—breast cancer	0.000178	0.000231	CcSEcCtD
Fosaprepitant—Rash—Gemcitabine—breast cancer	0.000178	0.000231	CcSEcCtD
Fosaprepitant—Dermatitis—Gemcitabine—breast cancer	0.000178	0.00023	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—breast cancer	0.000178	0.00023	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—breast cancer	0.000178	0.00023	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Headache—Gemcitabine—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—Dyspepsia—Docetaxel—breast cancer	0.000177	0.000229	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—AGTR1—breast cancer	0.000176	0.000787	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRL—breast cancer	0.000176	0.000787	CbGpPWpGaD
Fosaprepitant—Insomnia—Capecitabine—breast cancer	0.000176	0.000227	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—breast cancer	0.000176	0.000227	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—breast cancer	0.000175	0.000227	CcSEcCtD
Fosaprepitant—Dermatitis—Fluorouracil—breast cancer	0.000175	0.000227	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—breast cancer	0.000175	0.000226	CcSEcCtD
Fosaprepitant—Hypersensitivity—Paclitaxel—breast cancer	0.000175	0.000226	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—breast cancer	0.000174	0.000225	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—breast cancer	0.000174	0.000225	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—breast cancer	0.000174	0.000225	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—STK11—breast cancer	0.000173	0.000775	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADAM10—breast cancer	0.000173	0.000775	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Dyspnoea—Capecitabine—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—breast cancer	0.000173	0.000224	CcSEcCtD
Fosaprepitant—Nausea—Mitoxantrone—breast cancer	0.000173	0.000223	CcSEcCtD
Fosaprepitant—Nausea—Irinotecan—breast cancer	0.000173	0.000223	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—breast cancer	0.000172	0.000223	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—breast cancer	0.000172	0.000222	CcSEcCtD
Fosaprepitant—Constipation—Docetaxel—breast cancer	0.000172	0.000222	CcSEcCtD
Fosaprepitant—Pain—Docetaxel—breast cancer	0.000172	0.000222	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PLG—breast cancer	0.000171	0.000767	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Capecitabine—breast cancer	0.000171	0.000221	CcSEcCtD
Fosaprepitant—Asthenia—Paclitaxel—breast cancer	0.00017	0.00022	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—AKT2—breast cancer	0.00017	0.000758	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Capecitabine—breast cancer	0.000169	0.000219	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGF10—breast cancer	0.000169	0.000754	CbGpPWpGaD
Fosaprepitant—Nausea—Gemcitabine—breast cancer	0.000168	0.000217	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Capecitabine—breast cancer	0.000168	0.000217	CcSEcCtD
Fosaprepitant—Fatigue—Capecitabine—breast cancer	0.000168	0.000217	CcSEcCtD
Fosaprepitant—Pruritus—Paclitaxel—breast cancer	0.000168	0.000217	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—breast cancer	0.000167	0.000216	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—breast cancer	0.000167	0.000216	CcSEcCtD
Fosaprepitant—Constipation—Capecitabine—breast cancer	0.000166	0.000215	CcSEcCtD
Fosaprepitant—Pain—Capecitabine—breast cancer	0.000166	0.000215	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—breast cancer	0.000166	0.000215	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—breast cancer	0.000166	0.000215	CcSEcCtD
Fosaprepitant—Feeling abnormal—Docetaxel—breast cancer	0.000165	0.000214	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—breast cancer	0.000165	0.000214	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—breast cancer	0.000165	0.000213	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—breast cancer	0.000165	0.000213	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—breast cancer	0.000164	0.000213	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Docetaxel—breast cancer	0.000164	0.000212	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—breast cancer	0.000164	0.000212	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—breast cancer	0.000164	0.000212	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—breast cancer	0.000164	0.000212	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—breast cancer	0.000164	0.000211	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CD—breast cancer	0.000163	0.000728	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDGFA—breast cancer	0.000163	0.000728	CbGpPWpGaD
Fosaprepitant—Dysgeusia—Epirubicin—breast cancer	0.000163	0.00021	CcSEcCtD
Fosaprepitant—Diarrhoea—Paclitaxel—breast cancer	0.000162	0.00021	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TGFBR2—breast cancer	0.00016	0.000717	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Capecitabine—breast cancer	0.00016	0.000207	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—breast cancer	0.00016	0.000207	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—breast cancer	0.00016	0.000207	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—breast cancer	0.00016	0.000206	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—breast cancer	0.000159	0.000206	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Capecitabine—breast cancer	0.000159	0.000206	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—breast cancer	0.000159	0.000206	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—breast cancer	0.000159	0.000205	CcSEcCtD
Fosaprepitant—Abdominal pain—Docetaxel—breast cancer	0.000159	0.000205	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ITPR1—breast cancer	0.000158	0.000706	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB4—breast cancer	0.000157	0.000701	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP3—breast cancer	0.000157	0.000701	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT5A—breast cancer	0.000157	0.000701	CbGpPWpGaD
Fosaprepitant—Dizziness—Paclitaxel—breast cancer	0.000157	0.000203	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CB—breast cancer	0.000156	0.000699	CbGpPWpGaD
Fosaprepitant—Cough—Methotrexate—breast cancer	0.000155	0.0002	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—breast cancer	0.000155	0.0002	CcSEcCtD
Fosaprepitant—Urticaria—Capecitabine—breast cancer	0.000154	0.0002	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—breast cancer	0.000154	0.000199	CcSEcCtD
Fosaprepitant—Abdominal pain—Capecitabine—breast cancer	0.000154	0.000199	CcSEcCtD
Fosaprepitant—Body temperature increased—Capecitabine—breast cancer	0.000154	0.000199	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—breast cancer	0.000154	0.000199	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—breast cancer	0.000154	0.000199	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—breast cancer	0.000153	0.000198	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SMAD4—breast cancer	0.000152	0.000679	CbGpPWpGaD
Fosaprepitant—Flatulence—Doxorubicin—breast cancer	0.000151	0.000196	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IGF1R—breast cancer	0.000151	0.000675	CbGpPWpGaD
Fosaprepitant—Chest pain—Methotrexate—breast cancer	0.000151	0.000195	CcSEcCtD
Fosaprepitant—Vomiting—Paclitaxel—breast cancer	0.000151	0.000195	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—breast cancer	0.00015	0.000194	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—breast cancer	0.00015	0.000672	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.00015	0.000194	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—breast cancer	0.00015	0.000194	CcSEcCtD
Fosaprepitant—Rash—Paclitaxel—breast cancer	0.000149	0.000193	CcSEcCtD
Fosaprepitant—Dermatitis—Paclitaxel—breast cancer	0.000149	0.000193	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—breast cancer	0.000149	0.000193	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—breast cancer	0.000149	0.000192	CcSEcCtD
Fosaprepitant—Headache—Paclitaxel—breast cancer	0.000148	0.000192	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HES1—breast cancer	0.000148	0.000663	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Docetaxel—breast cancer	0.000148	0.000191	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—breast cancer	0.000148	0.000191	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NCOR1—breast cancer	0.000147	0.000659	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLA2G4A—breast cancer	0.000147	0.000659	CbGpPWpGaD
Fosaprepitant—Palpitations—Epirubicin—breast cancer	0.000147	0.00019	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—breast cancer	0.000146	0.000189	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CSF2—breast cancer	0.000146	0.000652	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF1—breast cancer	0.000146	0.000652	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RAF1—breast cancer	0.000145	0.00065	CbGpPWpGaD
Fosaprepitant—Cough—Epirubicin—breast cancer	0.000145	0.000187	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NRG1—breast cancer	0.000145	0.000647	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Methotrexate—breast cancer	0.000145	0.000187	CcSEcCtD
Fosaprepitant—Asthenia—Docetaxel—breast cancer	0.000144	0.000186	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—breast cancer	0.000144	0.000186	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—H2AFX—breast cancer	0.000144	0.000642	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IL2—breast cancer	0.000144	0.000642	CbGpPWpGaD
Fosaprepitant—Hypertension—Epirubicin—breast cancer	0.000143	0.000185	CcSEcCtD
Fosaprepitant—Hypersensitivity—Capecitabine—breast cancer	0.000143	0.000185	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—E2F1—breast cancer	0.000143	0.000638	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Doxorubicin—breast cancer	0.000142	0.000184	CcSEcCtD
Fosaprepitant—Pruritus—Docetaxel—breast cancer	0.000142	0.000184	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CB—breast cancer	0.000142	0.000635	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Methotrexate—breast cancer	0.000142	0.000184	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—breast cancer	0.000142	0.000184	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—breast cancer	0.000141	0.000183	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—breast cancer	0.000141	0.000182	CcSEcCtD
Fosaprepitant—Nausea—Paclitaxel—breast cancer	0.000141	0.000182	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—breast cancer	0.000141	0.000182	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.00014	0.000181	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—breast cancer	0.00014	0.000181	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—breast cancer	0.00014	0.000181	CcSEcCtD
Fosaprepitant—Asthenia—Capecitabine—breast cancer	0.000139	0.00018	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—breast cancer	0.000138	0.000179	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—breast cancer	0.000138	0.000179	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—breast cancer	0.000138	0.000178	CcSEcCtD
Fosaprepitant—Pruritus—Capecitabine—breast cancer	0.000138	0.000178	CcSEcCtD
Fosaprepitant—Diarrhoea—Docetaxel—breast cancer	0.000137	0.000178	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SPP1—breast cancer	0.000137	0.000613	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—breast cancer	0.000136	0.00061	CbGpPWpGaD
Fosaprepitant—Palpitations—Doxorubicin—breast cancer	0.000136	0.000175	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ERBB3—breast cancer	0.000136	0.000606	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Epirubicin—breast cancer	0.000135	0.000175	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—breast cancer	0.000135	0.000175	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGFR2—breast cancer	0.000135	0.000605	CbGpPWpGaD
Fosaprepitant—Hypotension—Methotrexate—breast cancer	0.000135	0.000175	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—breast cancer	0.000135	0.000175	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—breast cancer	0.000135	0.000174	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—breast cancer	0.000134	0.000173	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—breast cancer	0.000133	0.000172	CcSEcCtD
Fosaprepitant—Diarrhoea—Capecitabine—breast cancer	0.000133	0.000172	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—breast cancer	0.000133	0.000172	CcSEcCtD
Fosaprepitant—Dizziness—Docetaxel—breast cancer	0.000133	0.000172	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—breast cancer	0.000133	0.000171	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—breast cancer	0.000132	0.00017	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—breast cancer	0.000131	0.000169	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—breast cancer	0.000131	0.000169	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—breast cancer	0.000131	0.000169	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—IL2—breast cancer	0.00013	0.000583	CbGpPWpGaD
Fosaprepitant—Anxiety—Doxorubicin—breast cancer	0.00013	0.000168	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TERT—breast cancer	0.00013	0.000581	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.00013	0.000168	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—breast cancer	0.000129	0.000167	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—breast cancer	0.000129	0.000167	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—breast cancer	0.000129	0.000166	CcSEcCtD
Fosaprepitant—Dizziness—Capecitabine—breast cancer	0.000129	0.000166	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—breast cancer	0.000128	0.000165	CcSEcCtD
Fosaprepitant—Vomiting—Docetaxel—breast cancer	0.000128	0.000165	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—breast cancer	0.000127	0.000165	CcSEcCtD
Fosaprepitant—Rash—Docetaxel—breast cancer	0.000127	0.000164	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—breast cancer	0.000127	0.000164	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—breast cancer	0.000126	0.000164	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FGFR1—breast cancer	0.000126	0.000564	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Methotrexate—breast cancer	0.000126	0.000163	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—breast cancer	0.000126	0.000163	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—breast cancer	0.000125	0.000162	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—breast cancer	0.000125	0.000162	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—breast cancer	0.000125	0.000162	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—breast cancer	0.000125	0.000161	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—breast cancer	0.000125	0.000161	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HIF1A—breast cancer	0.000124	0.000556	CbGpPWpGaD
Fosaprepitant—Pain—Methotrexate—breast cancer	0.000124	0.00016	CcSEcCtD
Fosaprepitant—Vomiting—Capecitabine—breast cancer	0.000124	0.00016	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—breast cancer	0.000123	0.000159	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—breast cancer	0.000123	0.000159	CcSEcCtD
Fosaprepitant—Rash—Capecitabine—breast cancer	0.000123	0.000159	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—breast cancer	0.000123	0.000158	CcSEcCtD
Fosaprepitant—Dermatitis—Capecitabine—breast cancer	0.000122	0.000158	CcSEcCtD
Fosaprepitant—Headache—Capecitabine—breast cancer	0.000122	0.000157	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—breast cancer	0.000122	0.000157	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—LEP—breast cancer	0.000121	0.000542	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Doxorubicin—breast cancer	0.000121	0.000157	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—breast cancer	0.000121	0.000156	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—breast cancer	0.00012	0.000156	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CAV1—breast cancer	0.00012	0.000537	CbGpPWpGaD
Fosaprepitant—Nausea—Docetaxel—breast cancer	0.000119	0.000154	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—breast cancer	0.000119	0.000154	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—breast cancer	0.000119	0.000154	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—KDR—breast cancer	0.000119	0.000531	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Methotrexate—breast cancer	0.000118	0.000153	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—breast cancer	0.000118	0.000152	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—breast cancer	0.000117	0.000151	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—breast cancer	0.000117	0.000151	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—breast cancer	0.000117	0.000151	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ESR1—breast cancer	0.000116	0.000518	CbGpPWpGaD
Fosaprepitant—Pain—Epirubicin—breast cancer	0.000116	0.00015	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—breast cancer	0.000116	0.00015	CcSEcCtD
Fosaprepitant—Nausea—Capecitabine—breast cancer	0.000115	0.000149	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—breast cancer	0.000115	0.000149	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FN1—breast cancer	0.000114	0.000511	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Methotrexate—breast cancer	0.000114	0.000148	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—breast cancer	0.000114	0.000148	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—breast cancer	0.000113	0.000147	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NFKBIA—breast cancer	0.000113	0.000505	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH1—breast cancer	0.000112	0.000501	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Doxorubicin—breast cancer	0.000112	0.000144	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—breast cancer	0.000112	0.000144	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—breast cancer	0.000111	0.000144	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—breast cancer	0.000111	0.000143	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—breast cancer	0.00011	0.000143	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—breast cancer	0.00011	0.000489	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APC—breast cancer	0.00011	0.000489	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KIT—breast cancer	0.00011	0.000489	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Doxorubicin—breast cancer	0.000109	0.000141	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—EGF—breast cancer	0.000108	0.000484	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000108	0.00014	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—breast cancer	0.000108	0.00014	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—breast cancer	0.000108	0.000139	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—breast cancer	0.000107	0.000139	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—breast cancer	0.000107	0.000139	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—breast cancer	0.000107	0.000138	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—breast cancer	0.000107	0.000138	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—breast cancer	0.000107	0.000138	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK3—breast cancer	0.000105	0.000469	CbGpPWpGaD
Fosaprepitant—Asthenia—Methotrexate—breast cancer	0.000104	0.000134	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—breast cancer	0.000103	0.000134	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—BRAF—breast cancer	0.000103	0.00046	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—breast cancer	0.000102	0.000133	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—breast cancer	0.000102	0.000132	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—breast cancer	0.0001	0.000448	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT2—breast cancer	0.0001	0.000448	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Epirubicin—breast cancer	9.98e-05	0.000129	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—breast cancer	9.98e-05	0.000446	CbGpPWpGaD
Fosaprepitant—Urticaria—Doxorubicin—breast cancer	9.96e-05	0.000129	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—breast cancer	9.91e-05	0.000128	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—breast cancer	9.91e-05	0.000128	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—breast cancer	9.9e-05	0.000128	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—breast cancer	9.72e-05	0.000126	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CD—breast cancer	9.63e-05	0.00043	CbGpPWpGaD
Fosaprepitant—Pruritus—Epirubicin—breast cancer	9.58e-05	0.000124	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—breast cancer	9.57e-05	0.000124	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—breast cancer	9.53e-05	0.000426	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—breast cancer	9.52e-05	0.000426	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KRAS—breast cancer	9.42e-05	0.000421	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Epirubicin—breast cancer	9.27e-05	0.00012	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—breast cancer	9.23e-05	0.000119	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—breast cancer	9.2e-05	0.000119	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—breast cancer	9.13e-05	0.000118	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—breast cancer	9.12e-05	0.000118	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—breast cancer	9.09e-05	0.000406	CbGpPWpGaD
Fosaprepitant—Headache—Methotrexate—breast cancer	9.07e-05	0.000117	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—breast cancer	8.99e-05	0.000116	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—breast cancer	8.96e-05	0.000116	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—breast cancer	8.87e-05	0.000115	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—breast cancer	8.66e-05	0.000387	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MDM2—breast cancer	8.62e-05	0.000385	CbGpPWpGaD
Fosaprepitant—Vomiting—Epirubicin—breast cancer	8.61e-05	0.000111	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—breast cancer	8.6e-05	0.000111	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RAF1—breast cancer	8.59e-05	0.000384	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Doxorubicin—breast cancer	8.57e-05	0.000111	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RELA—breast cancer	8.56e-05	0.000382	CbGpPWpGaD
Fosaprepitant—Rash—Epirubicin—breast cancer	8.54e-05	0.00011	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—breast cancer	8.53e-05	0.00011	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ERBB2—breast cancer	8.5e-05	0.00038	CbGpPWpGaD
Fosaprepitant—Headache—Epirubicin—breast cancer	8.48e-05	0.00011	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MTOR—breast cancer	8.39e-05	0.000375	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CB—breast cancer	8.39e-05	0.000375	CbGpPWpGaD
Fosaprepitant—Dizziness—Doxorubicin—breast cancer	8.29e-05	0.000107	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—breast cancer	8.06e-05	0.00036	CbGpPWpGaD
Fosaprepitant—Nausea—Epirubicin—breast cancer	8.04e-05	0.000104	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—HRAS—breast cancer	8.01e-05	0.000358	CbGpPWpGaD
Fosaprepitant—Vomiting—Doxorubicin—breast cancer	7.97e-05	0.000103	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—breast cancer	7.9e-05	0.000102	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—breast cancer	7.89e-05	0.000102	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1B—breast cancer	7.87e-05	0.000352	CbGpPWpGaD
Fosaprepitant—Headache—Doxorubicin—breast cancer	7.85e-05	0.000102	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—breast cancer	7.79e-05	0.000348	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—breast cancer	7.72e-05	0.000345	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL2—breast cancer	7.71e-05	0.000344	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—breast cancer	7.67e-05	0.000343	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCND1—breast cancer	7.51e-05	0.000336	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—JUN—breast cancer	7.5e-05	0.000335	CbGpPWpGaD
Fosaprepitant—Nausea—Doxorubicin—breast cancer	7.44e-05	9.63e-05	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CTNNB1—breast cancer	7.44e-05	0.000333	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—breast cancer	7.29e-05	0.000326	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1A—breast cancer	7.27e-05	0.000325	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTEN—breast cancer	7.25e-05	0.000324	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK8—breast cancer	7.09e-05	0.000317	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—breast cancer	7.07e-05	0.000316	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SRC—breast cancer	6.72e-05	0.000301	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—breast cancer	6.55e-05	0.000293	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—breast cancer	6.48e-05	0.00029	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK3—breast cancer	6.19e-05	0.000277	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—breast cancer	6.03e-05	0.000269	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—breast cancer	6.01e-05	0.000269	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—breast cancer	5.89e-05	0.000263	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KRAS—breast cancer	5.57e-05	0.000249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—breast cancer	5.11e-05	0.000229	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—breast cancer	4.95e-05	0.000221	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRAS—breast cancer	4.73e-05	0.000212	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—breast cancer	4.53e-05	0.000202	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—breast cancer	4.18e-05	0.000187	CbGpPWpGaD
